Using a monoclonal antibody to protect the heart after a heart attack
Official title: Targeting a ectonucleotidase in the heart with a monoclonal antibody to prevent post-infarct heart failure
Funded at University of California Los Angeles · NIH-10904984 · Data updated 2026-11-12
This study is looking at how a special treatment can help your heart heal better after a heart attack by blocking a specific enzyme that makes recovery harder, with the hope of preventing heart failure for people like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | August 14, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $737,132 |
| NIH project number | 5R01HL169217-02 |
| Project ID | NIH-10904984 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have recently experienced a myocardial infarction and are at risk of developing heart failure.
✕Less likely to help
Patients who have not had a heart attack or those with pre-existing heart failure may not benefit from this research.
What this research studies
This research investigates how targeting a specific enzyme in the heart with a monoclonal antibody can help prevent heart failure following a heart attack. The study focuses on the role of ectonucleotidase ENPP1, which is known to increase after a heart attack and contribute to inflammation and poor healing. By inhibiting this enzyme, the research aims to improve cardiac repair and reduce the risk of heart failure in patients who have suffered a myocardial infarction. The approach involves both genetic and pharmacological methods to assess the effectiveness of this treatment.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve heart recovery and reduce the incidence of heart failure after heart attacks.
How similar studies have gone: While targeting ectonucleotidases is a relatively novel approach, previous research has shown promise in similar strategies for improving cardiac repair after injury.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Deb, Arjun — University of California Los Angeles
- Study coordinator: Deb, Arjun
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.